Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

BPC-157

Body Protection Compound-157, PL-14736, Pentadecapeptide BPC 157

Quick Stats
Studies 196
Trials 1
Score 2
2023 pubmed 7 citations

Pentadecapeptide BPC 157 as Therapy for Inferior Caval Vein Embolization: Recovery of Sodium Laurate-Post-Embolization Syndrome in Rats.

Smoday. Ivan Maria IM; Krezic. Ivan I; Kalogjera. Luka L; Vukovic. Vlasta V; Zizek. Helena H; Skoro. Marija M; Kovac. Katarina Kasnik KK; Vranes. Hrvoje H; Barisic. Ivan I; Sikiric. Suncana S; Strbe. Sanja S; Tepes. Marijan M; Oroz. Katarina K; Zubcic. Slavica S; Stupnisek. Mirjana M; Beketic Oreskovic. Lidija L; Kavelj. Ivana I; Novosel. Luka L; Prenc. Matea M; Barsic Ostojic. Sanja S; Dobric. Ivan I; Sever. Marko M; Blagaic. Alenka Boban AB; Skrtic. Anita A; Staresinic. Mario M; Sjekavica. Ivica I; Seiwerth. Sven S; Sikiric. Predrag P

Key Findings

  • BPC‑157 (10 µg/kg) given shortly after a lethal vein blockage reduced lung thromboemboli and organ lesions.
  • The peptide activated collateral vessels (e.g., azygos vein), restoring blood flow and lowering venous hypertension in the brain, portal system, and caval system.
  • Multiorgan failure signs (ECG disturbances, blood pressure drops, organ swelling) were markedly attenuated or eliminated with BPC‑157 treatment.

Practical Outcomes

  • The study suggests BPC‑157 might help repair severe vascular blockages and limit organ damage, but it is an animal model with no human data. For biohackers, the finding is interesting but not ready for direct use; the effective dose in rats was about 10 µg per kilogram given orally or intraperitoneally, and safety/efficacy in people remain unknown.

Summary

In rats that were given a chemical to block a big vein and cause severe organ damage, a tiny protein called BPC‑157 (given by mouth or injection) quickly helped restore blood flow, reduced clot‑related damage in the lungs, and protected the brain, heart, liver, kidneys and gut. The peptide seemed to open backup blood routes, especially the azygos vein, and lowered dangerous pressure spikes in the veins.

Abstract

After inferior caval vein embolization therapy, post-embolization syndrome (sodium laurate 10 mg/kg, 0.1 mL into rat inferior caval vein, assessment at 15, 30, 60 min, prime lung lesions, thromboemboli occluding lung vessels), as a severe occlusion/occlusion-like syndrome, might be resolved as a whole by stable gastric pentadecapeptide BPC 157 therapy. At 5 min after laurate injection, stable gastric pentadecapeptide BPC 157 was implemented as therapy (10 µg/kg, 10 ng/kg intraperitoneally or intragastrically). As before, confronted with the occlusion of major vessel(s) or similar noxious procedures, such as rapidly acting Virchow triad circumstances, the particular effect of the therapy (i.e., collateral pathways activation, "bypassing vascular key", i.e., direct blood flow delivery via activation of azygos vein) assisted in the recovery of the vessel/s and counteracted multiorgan failure due to occlusion/occlusion-like syndrome as a whole in the laurate-injected rats. Along with prime lung lesions and thromboemboli occluding lung vessels, post-embolization syndrome rapidly occurred peripherally and centrally as a shared multiorgan and vessel failure, brain, heart, lung, liver, kidney, and gastrointestinal tract lesions, venous hypertension (intracranial (superior sagittal sinus), portal, and caval), aortal hypotension, progressing thrombosis in veins and arteries and stasis, congested and/or failed major veins, and severe ECG disturbances. Whatever the cause, these were all counteracted, eliminated, or attenuated by the application of BPC 157 therapy. As recovery with BPC 157 therapy commonly and rapidly occurred, reversing the collapsed azygos vein to the rescuing collateral pathway might initiate rapid direct blood delivery and start blood flow reorganization. In conclusion, we suggest BPC 157 therapy to resolve further vascular and embolization injuries.

Study Information

Provider

pubmed

Year

2023

Date

2023-10-23T00:00:00.000Z

DOI

10.3390/ph16101507

Citations

7

References

75